Puma Biotechnology (NASDAQ:PBYI) Stock: Insider Michael Patrick Miller Sells 15,000 Shares

Puma Biotechnology, Inc. (NASDAQ:PBYI – Get Free Report) Director Michael Miller sold 15,000 shares of Puma Biotechnology stock in a transaction that occurred on Wednesday, November 11th. The shares were sold at an average price of $8.10, for a total transaction of $121,500.00. Following the sale, the director owned 66,000 shares of the company’s stock, valued at approximately $534,600. The trade was a 18.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Puma Biotechnology Price Performance

PBYI stock traded down $0.31 during midday trading on Friday, reaching $7.77. The company had a trading volume of 403,672 shares, compared to its average volume of 469,587. Puma Biotechnology, Inc. has a 1 year low of $4.76 and a 1 year high of $11.50. The company has a market capitalization of $401.69 million, a P/E ratio of 16.89 and a beta of 1.40. The firm has a 50-day moving average price of $9.75 and a 200-day moving average price of $8.02.

Puma Biotechnology (NASDAQ:PBYI – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.06. The firm had revenue of $55.06 million for the quarter, compared to analyst estimates of $57.50 million. Puma Biotechnology had a net margin of 10.26% and a return on equity of 17.50%. On average, equities analysts predict that Puma Biotechnology, Inc. will post 0.37 EPS for the current year.

Hedge Funds Weigh In On Puma Biotechnology

Large investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. lifted its stake in Puma Biotechnology by 16.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,419 shares of the biopharmaceutical company’s stock worth $92,000 after acquiring an additional 1,318 shares during the period. IFP Advisors Inc boosted its holdings in Puma Biotechnology by 20.4% in the third quarter. IFP Advisors Inc now owns 9,470 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 1,607 shares in the last quarter. State of Alaska Department of Revenue increased its position in Puma Biotechnology by 28.3% during the 3rd quarter. State of Alaska Department of Revenue now owns 10,834 shares of the biopharmaceutical company’s stock valued at $106,000 after purchasing an additional 2,389 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new position in Puma Biotechnology during the 3rd quarter valued at $26,000. Finally, Royal Bank of Canada increased its position in Puma Biotechnology by 244.5% during the 1st quarter. Royal Bank of Canada now owns 4,320 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 3,066 shares during the period. Hedge funds and other institutional investors own 61.29% of the company’s stock.

Wall Street Analysts Forecast Growth

PBYI has been the topic of a number of research analyst reports. Wall Street Zen cut Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Saturday. TD Cowen raised their price target on Puma Biotechnology from $5.00 to $6.00 and gave the company a “hold” rating in a research report on Friday, August 7th. Finally, Weiss Ratings lowered Puma Biotechnology from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday. Two equities research analysts have rated the stock with a Hold rating. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $6.00.

Check Out Our Latest Analysis on Puma Biotechnology

About Puma Biotechnology

(Get Free Report)

Puma Biotechnology is a biopharmaceutical company focused on developing and commercializing medicines for cancer treatment. Its work centers on targeted therapies, particularly treatments for breast cancer. The company’s principal product is Nerlynx (neratinib), an oral HER2-targeted medicine. In the United States, it is approved for certain patients with early-stage HER2-positive breast cancer following trastuzumab-based treatment, and for some patients with advanced or metastatic HER2-positive breast cancer in combination with capecitabine.

Recommended Stories

Insider Buying and Selling by Quarter for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.